PHARMACY

Walmart, Humana unveil new Medicare Part D prescription drug offering

BY Mike Troy

BENTONVILLE , Ark. (Oct. 1) Walmart and Humana on Friday unveiled a new Medicare Part D prescription drug offering designed to help both companies gain market share and save money for those enrolled in the program.

Co-branded as the Humana Walmart-Preferred Rx Plan, the program involves a $14.80 monthly premium that is less than half the weighted 2010 national average, generic drug co-payments as low as $2 at Walmart pharmacies and no co-payments for select generics filled via Humana’s RightSource home-delivery service. Humana and Walmart said the program has the potential to save Medicare Part D enrollees as much as $450 annually.

“People are more likely to take the medications prescribed for them when they can afford those medications,” said William Fleming, PharmD, VP Humana Pharmacy Solutions. “And adhering to prescription-drug regimens can enable people to be healthier and prevent future illness. At Humana, we believe that this prevention helps people live healthier lives and achieve lifelong well-being.”

John Agwunobi, M.D., president of Walmart’s Health and Wellness division said Walmart is uniquely qualified to help lower the cost of prescriptions because it is the world’s largest retailer.

“We know every dollar counts, especially when you live on a fixed income. We believe no one should have to choose between buying their groceries or their medications,” Agwunobi said.

He called the program an example of Walmart’s commitment to help people save money so they can live better.

It is also an example of how Walmart can bring more shoppers to its store. There are an estimated 18 million people enrolled in the Medicare Part D program, but that figure is forecast to grow to 26 million by 2015. Open enrollment in the program begins Nov. 15 and continues through the end of the year, and Humana and Walmart are undertaking an extensive media relations and marketing campaign to drive awareness and education. A key element involves kiosks in some 3,000 stores which will occasionally be staffed by Humana representatives.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Harris Teeter offers Rx savings

BY Allison Cerra

CHARLOTTE, N.C. Harris Teeter is offering customers more ways to save on their prescriptions.

The supermarket chain on Thursday announced an updated generic prescription savings club and the Harris Teeter Yourwellness savings card. The updated generic prescription savings club now offers customers a 30-day supply of generics for just $3.99, and has expanded its generic drug availabilities from 300 to 400 items. What’s more, Harris Teeter is providing up to a 30-day supply of five common generic diabetic medications for free. Enrollment is $4.95 per year.

Harris Teeter’s Yourwellness savings card, which costs $3.95 to enroll, offers shoppers savings on such health-and-wellness items as vitamins, eye care products and prescriptions. The new card program offers a choice of three plans: bronze, silver, or platinum.

Harris Teeter originally launched the yourwellness identity program in 2006. The goal, according to the company, is “to provide shoppers with evidence-based guidance on important health issues and to also help make it easier for shoppers to choose nutritional items in the store.”

Click here for more details on each program.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Teva unveils mid-stage clinical trial results for MS drug

BY Alaric DeArment

JERUSALEM Teva Pharmaceutical Industries and Active Biotech announced promising results from a mid-stage trial of laquinimod, a once-daily oral treatment for relapsing-remitting multiple sclerosis.

The companies released results of a phase-2 extension study of the drug indicating that it was safe for use in patients, but also reduced lesions that are a marker of disease activity by 52%. In addition, the study indicated that the drug reduced relapses of the disease and did not show evidence of suppression of the immune system. Results of the study were published online in the journal Multiple Sclerosis.

The two companies expect to see results of two phase-3 trials of the drug next year. The Food and Drug Administration gave fast-track designation to the drug in February 2009.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?